直真科技(003007.SZ)上半年預虧4300萬元
格隆匯7月13日丨直真科技(003007.SZ)披露2022年半年度業績預吿,公司預計2022年1-6月實現歸屬於上市公司股東的淨利潤為虧損4300萬元,上年同期為虧損6126.94萬元;扣除非經常性損益後的淨利潤虧損為4700萬元,上年同期為虧損6809.68萬元。
公司營業收入呈現明顯的季節性,第一至三季度較少,第四季度較多。而公司管理費用、銷售費用及研發費用的發生在各個季度較為平均,尤其公司研發費用投入較高,因此導致公司2022年上半年虧損。其中,虧損較上年同期收窄的主要原因繫上年末部分延遲驗收的軟件開發及技術服務項目,陸續在2022年上半年完成驗收,公司1-6月實現營業收入較上年同期有一定程度增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.